Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Gross Margin (2016 - 2025)

Historic Gross Margin for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to 77.8%.

  • Iradimed's Gross Margin rose 3600.0% to 77.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 77.07%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 76.94% for FY2024, which is 4300.0% up from last year.
  • Iradimed's Gross Margin amounted to 77.8% in Q3 2025, which was up 3600.0% from 78.17% recorded in Q2 2025.
  • Iradimed's Gross Margin's 5-year high stood at 79.71% during Q2 2022, with a 5-year trough of 74.74% in Q2 2021.
  • In the last 5 years, Iradimed's Gross Margin had a median value of 76.86% in 2023 and averaged 76.95%.
  • Per our database at Business Quant, Iradimed's Gross Margin skyrocketed by 49700bps in 2022 and then tumbled by -41600bps in 2023.
  • Quarter analysis of 5 years shows Iradimed's Gross Margin stood at 77.91% in 2021, then dropped by -3bps to 75.49% in 2022, then increased by 2bps to 76.86% in 2023, then decreased by -1bps to 76.13% in 2024, then grew by 2bps to 77.8% in 2025.
  • Its Gross Margin stands at 77.8% for Q3 2025, versus 78.17% for Q2 2025 and 76.08% for Q1 2025.